Literature DB >> 20382241

Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

Rachmat Hidajat1, Seraphin Kuate, David Venzon, Vaniambadi Kalyanaraman, Irene Kalisz, James Treece, Ying Lian, Susan W Barnett, Marjorie Robert-Guroff.   

Abstract

An HIV Env immunogen capable of eliciting broad immunity is critical for a successful vaccine. We constructed and characterized adenovirus 5 host range mutant (Ad5hr) recombinants encoding HIV(SF162) gp160 (subtype B) and HIV(TV1) gp160 (subtype C). Immunization of mice with one or both induced cellular immunity to subtype B and C peptides by ELISpot, and antibody responses with high binding titers to HIV Env of subtypes A, B, C, and E. Notably, Ad5hr-HIV(TV1) gp160 induced better cellular immunity than Ad5hr-HIV(SF162) gp160, either alone or following co-administration. Thus, the TV1 Env recombinant alone may be sufficient for eliciting immune responses against both subtype B and C envelopes. Further studies of Ad5hr-HIV(TV1) gp160 in rhesus macaques will evaluate the suitability of this insert for a future phase I clinical trial using a replication-competent Ad4 vector. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382241      PMCID: PMC2875308          DOI: 10.1016/j.vaccine.2010.03.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  48 in total

1.  The pathogenesis of sexual mucosal transmission and early stages of infection: obstacles and a narrow window of opportunity for prevention.

Authors:  A T Haase
Journal:  AIDS       Date:  2001-02       Impact factor: 4.177

Review 2.  Adenovirus immunoregulatory genes and their cellular targets.

Authors:  M S Horwitz
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

3.  Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion.

Authors:  L Jean Patterson; Gregory A Prince; Ersell Richardson; W Gregory Alvord; Narender Kalyan; Marjorie Robert-Guroff
Journal:  Virology       Date:  2002-01-05       Impact factor: 3.616

Review 4.  Functions and mechanisms of action of the adenovirus E3 proteins.

Authors:  Drew L Lichtenstein; Karoly Toth; Konstantin Doronin; Ann E Tollefson; William S M Wold
Journal:  Int Rev Immunol       Date:  2004 Jan-Apr       Impact factor: 5.311

5.  A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.

Authors:  Nina Malkevitch; L Jean Patterson; Kristine Aldrich; Ersell Richardson; W Gregory Alvord; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

6.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

Authors:  L Jean Patterson; Nina Malkevitch; Joel Pinczewski; David Venzon; Yuanmei Lou; Bo Peng; Cindy Munch; Melissa Leonard; Ersell Richardson; Kristine Aldrich; V S Kalyanaraman; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation.

Authors:  Regina Hofmann-Lehmann; Josef Vlasak; Alison L Williams; Agnès-Laurence Chenine; Harold M McClure; Daniel C Anderson; Shawn O'Neil; Ruth M Ruprecht
Journal:  AIDS       Date:  2003-01-24       Impact factor: 4.177

9.  Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Authors:  L Jean Patterson; Nina Malkevitch; David Venzon; Joel Pinczewski; Victor Raúl Gómez-Román; Liqun Wang; V S Kalyanaraman; Phillip D Markham; Frank A Robey; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants.

Authors:  Jun Zhao; Yuanmei Lou; Joel Pinczewski; Nina Malkevitch; Kristine Aldrich; V S Kalyanaraman; David Venzon; Bo Peng; L Jean Patterson; Yvette Edghill-Smith; Ruth Woodward; George N Pavlakis; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

View more
  5 in total

1.  Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.

Authors:  L Jean Patterson; Seraphin Kuate; Mara Daltabuit-Test; Qingsheng Li; Peng Xiao; Katherine McKinnon; Janet DiPasquale; Anthony Cristillo; David Venzon; Ashley Haase; Marjorie Robert-Guroff
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.

Authors:  Jason S Richardson; Stéphane Pillet; Alexander J Bello; Gary P Kobinger
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

3.  MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.

Authors:  Erica A Mendes; Bráulia C Caetano; Marcus L O Penido; Oscar Bruna-Romero; Ricardo T Gazzinelli
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

4.  The use of adenoviral vectors in gene therapy and vaccine approaches.

Authors:  Natália Meneses Araújo; Ileana Gabriela Sanchez Rubio; Nicholas Pietro Agulha Toneto; Mirian Galliote Morale; Rodrigo Esaki Tamura
Journal:  Genet Mol Biol       Date:  2022-10-07       Impact factor: 2.087

5.  Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.

Authors:  Michael A Thomas; Rui Song; Thorsten Demberg; Diego A Vargas-Inchaustegui; David Venzon; Marjorie Robert-Guroff
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.